Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top 10 Lessons Learned

[1]  D. Fedorenko,et al.  Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. , 2012, Experimental hematology.

[2]  J. Petkau,et al.  Treatment With Interferon Beta for Multiple Sclerosis—Reply , 2012 .

[3]  H. Atkins,et al.  Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  J. Ouyang,et al.  Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China , 2012, Neurological Sciences.

[5]  P. Gustafson,et al.  Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. , 2012, JAMA.

[6]  M. Sormani,et al.  Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience , 2012, Multiple sclerosis.

[7]  Meena Subramanyam,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.

[8]  Craig I Coleman,et al.  Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States , 2012, Journal of medical economics.

[9]  H. Atkins,et al.  A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper , 2012, Multiple sclerosis.

[10]  H. Sullivan,et al.  A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. , 2011, Blood.

[11]  K. Khalili,et al.  Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  M. Béné,et al.  CD49d blockade by natalizumab therapy in patients with multiple sclerosis increases immature B-lymphocytes , 2011, Bone Marrow Transplantation.

[13]  C. Hawkey,et al.  Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation , 2011, Bone Marrow Transplantation.

[14]  G. Kraft,et al.  Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results , 2011, Bone Marrow Transplantation.

[15]  A. Flügel,et al.  CXCL12 expression within the CNS contributes to the resistance against experimental autoimmune encephalomyelitis in Albino Oxford rats. , 2011, Immunobiology.

[16]  M. Labopin,et al.  Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. , 2011, Blood.

[17]  D. Maloney,et al.  In‐vivo purging of the circulating clonal T‐cells with Alemtuzumab prior to autologous peripheral blood hematopoietic cell mobilization and transplantation , 2011, British journal of haematology.

[18]  A. Chappel,et al.  Cost-effectiveness of disease-modifying therapy for multiple sclerosis , 2011, Neurology.

[19]  S. Dikmen,et al.  Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Trojano,et al.  Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? , 2011, Neurologic clinics.

[21]  Yaou Liu,et al.  Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population , 2011, Annals of Hematology.

[22]  K. Schoelles,et al.  Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review , 2011, Multiple sclerosis.

[23]  K. O’Day,et al.  Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis , 2011, Journal of medical economics.

[24]  Xueqiang Hu,et al.  A Preliminary Result of Treatment of Neuromyelitis Optica With Autologous Peripheral Hematopoietic Stem Cell Transplantation , 2010, The neurologist.

[25]  H. Atkins.  Hematopoietic SCT for the treatment of multiple sclerosis , 2010, Bone Marrow Transplantation.

[26]  D. Arnold,et al.  Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  P. Tappenden,et al.  Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis , 2010, Bone Marrow Transplantation.

[28]  G. Gronseth,et al.  Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis , 2010, Neurology.

[29]  Gilles Edan,et al.  Evidence for a two-stage disability progression in multiple sclerosis , 2010, Brain : a journal of neurology.

[30]  E. Havrdová,et al.  High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience , 2010, Multiple sclerosis.

[31]  M. Labopin,et al.  Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases , 2010, Haematologica.

[32]  H. Reichmann,et al.  CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function , 2010, Bone Marrow Transplantation.

[33]  M. Chamberlain.  Neurotoxicity of Cancer Treatment , 2010, Current oncology reports.

[34]  Katherine A Myszka,et al.  Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. , 2009, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[35]  A. al‐Sabbagh,et al.  Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis , 2009, Journal of managed care pharmacy : JMCP.

[36]  A. Testori,et al.  Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study , 2009, The Lancet Neurology.

[37]  J. Lundgren,et al.  Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation , 2009, Multiple sclerosis.

[38]  H. Hartung,et al.  The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. , 2008, Blood.

[39]  Kai-Hsin Chang,et al.  Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. , 2008, Blood.

[40]  D. Kazis,et al.  Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome , 2008, Multiple sclerosis.

[41]  A. Madec,et al.  The CXCR4/CXCL12 (SDF‐1) signalling pathway protects non‐obese diabetic mouse from autoimmune diabetes , 2007, Clinical and experimental immunology.

[42]  B. Cohen,et al.  Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. , 2007, Blood.

[43]  E. Havrdová,et al.  Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database , 2006, Multiple sclerosis.

[44]  S. Wan,et al.  Autologous Peripheral Blood Stem Cell Transplantation for Severe Multiple Sclerosis , 2006, International journal of hematology.

[45]  J. Ouyang,et al.  Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients , 2006, Clinical transplantation.

[46]  D. Arnold,et al.  Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis , 2006, Neurology.

[47]  P. Fu,et al.  Randomised comparison of two B‐cell purging protocols for patients with B‐cell non‐Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34+ cell enrichment device , 2006, British journal of haematology.

[48]  G. Comi,et al.  Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis , 2005, Multiple sclerosis.

[49]  M. Filippi,et al.  Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. , 2005, Blood.

[50]  H. Atkins,et al.  Immunoablative therapy as a treatment aggressive multiple sclerosis. , 2005, Neurologic clinics.

[51]  Y. Blanco,et al.  Autologous haematopoietic-stem-cell transplantation for multiple sclerosis , 2005, The Lancet Neurology.

[52]  G. Kraft,et al.  High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. , 2003, Blood.

[53]  B. Cohen,et al.  Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. , 2003, Blood.

[54]  M. Mayes,et al.  Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[55]  E. Montserrat,et al.  CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. , 2003, Haematologica.

[56]  H. Hartung,et al.  Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial , 2002, The Lancet.

[57]  L. Weiner,et al.  Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[58]  L. Weiner,et al.  Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor , 2000, Neurology.

[59]  E. Havrdová,et al.  High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis , 2000, Bone Marrow Transplantation.

[60]  S. Goldberg,et al.  Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  J. Rose,et al.  Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis , 1997, Bone Marrow Transplantation.

[62]  A. Ben-nun,et al.  Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. , 1993, The Journal of clinical investigation.

[63]  O. Hommes,et al.  Determination of cyclophosphamide in urine, serum and cerebrospinal fluid of multiple sclerosis patients by field desorption mass spectrometry. , 1980, Clinica chimica acta; international journal of clinical chemistry.

[64]  S. Emerson,et al.  Immune reconstitution: how it should work, what's broken, and why it matters. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[65]  A. Anagnostopoulos,et al.  Autologous Stem Cell Transplantation in Progressive Multiple Sclerosis—An Interim Analysis of Efficacy , 2004, Journal of Clinical Immunology.

[66]  S. Eksborg,et al.  Pharmacokinetic and metabolic studies of high-dose busulphan in adults , 2004, European Journal of Clinical Pharmacology.

[67]  M. Mancini,et al.  Autologous peripheral blood stem cell transplantation in a patient with multiple sclerosis and concomitant Ph+ acute leukemia. , 1999, Haematologica.

[68]  A. Marmont.  Stem cell transplantation for severe autoimmune diseases: progress and problems. , 1998, Haematologica.